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Hepatitis C virus (HCV) persistently infects approximately 71 million people globally. To
prevent infection a vaccine which elicits neutralizing antibodies against the virus envelope
proteins (E1/E2) which are required for entry into host cells is desirable. DNA vaccines are
cost-effective to manufacture globally and despite recent landmark studies highlighting
the therapeutic efficacy of DNA vaccines in humans against cervical cancer, DNA
vaccines encoding E1/E2 developed thus far are poorly immunogenic. We now report
a novel and highly immunogenic DNA vaccination strategy that incorporates secreted
E1 and E2 (sE1 and sE2) into oligomers by fusion with the oligomerization domain
of the C4b-binding protein, IMX313P. The FDA approved plasmid, pVax, was used
to encode sE1, sE2, or sE1E2 with or without IMX313P, and intradermal prime-boost
vaccination studies in BALB/c mice showed that vaccines encoding IMX313P were
the most effective in eliciting humoral and cell-mediated immunity against the envelope
proteins. Further boosting with recombinant E1E2 proteins but not DNA nor virus-like
particles (VLPs) expressing E1E2 increased the immunogenicity of the DNA prime-boost
regimen. Nevertheless, the antibodies generated by the homologous DNA prime-boost
vaccinations more effectively inhibited the binding of VLPs to target cells and neutralized
transduction with HCV pseudoparticles (HCVpp) derived from different genotypes
including genotypes 1, 2, 3, 4, 5, and 6. This report provides the first evidence that
IMX313P can be used as an adjuvant for E1/E2-based DNA vaccines and represents a
translatable approach for the development of a HCV DNA vaccine.
Keywords: hepatitis C vaccine, viral hepatitis, HCV envelope proteins, preventative vaccination, DNA vaccine,
immune response, liver disease, IMX313P
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INTRODUCTION
Current estimates have shown that more than 71 million people
are living with chronic hepatitis C and a large proportion of these
individuals are at risk of developing cirrhosis that may progress
to hepatocellular carcinoma (1, 2). In 2015, viral hepatitis caused
1.34 million deaths and surpassed human immunodeficiency
virus (HIV) as a cause of mortality worldwide (1). The
introduction of direct acting antivirals (DAA), developed to
disrupt the function of critical non-structural (NS) HCV proteins
involved in viral replication, has been highly effective, resulting
in a reduced duration of treatment and high cure rates in most
patients, compared to pegylated interferon plus ribavirin (3).
However, the high cost of the DAA limits their use particularly
in low- to middle-income regions (4–6). Furthermore, it is
believed that only 20% of HCV-infected persons are aware
of their diagnosis while approximately 7.4% (or 1.1 million
persons) of those diagnosed receive treatment and an estimated
1.75 million new HCV infections occurred worldwide in 2015
(1). An additional challenge to DAA treatment includes the
potential for reinfection after treatment (7). For these reasons, the
development of an inexpensive, safe and effective HCV vaccine is
required to control the HCV epidemic worldwide and reduce the
financial stress on healthcare systems.
The development of a prophylactic HCV vaccine has been
difficult due to several factors including the high genetic
heterogeneity of the virus and its ability to escape the immune
defense of the infected host. The early induction of broad
neutralizing antibodies (NAb) and CD4+ and CD8+ T cell
responses directed against HCV structural and NS proteins are
thought to correlate with recovery from acute HCV infection (8–
11). The HCV envelope glycoproteins (E1 and E2) interact with
several receptor proteins, including CD81 and the tight junction
proteins claudin (CLDN) and occludin (OCLN) (12, 13) to
facilitate virus entry into host cells (14, 15). Consequently, E1 and
E2 have been the targets of various trials which aimed to induce
protective NAb (16–23). Previous studies have shown that NAb
to epitopes in the HCV E1 and E2 are protective against several
genotypes of HCV (24–29). Besides NAb, numerous studies have
shown that the induction of cell-mediated immunity (CMI) is
linked to the clearance of HCV infection (30) and depletion of
CD4+ or CD8+ T cells has been reported to lead to persistent
infection in chimpanzees (31, 32). Therefore, a vaccine capable of
eliciting NAb and T-cell immunity is desirable.
The vaccine efficacy data from HCV challenge studies
in chimpanzees [reviewed in (33)], further highlighted the
importance of NAb in providing protection against HCV.
Previous reports have demonstrated that NAb present in HCV
patient sera are protective against homologous- (34) and
heterologous- HCV challenge in passively immunized chimeric
human liver SCID/uPa mice (35, 36). Vaccination of these
mice with a recombinant vaccinia virus vaccine encoding the
HCV structural proteins was also shown to generate protection
against HCV challenge (37). Chimpanzees vaccinated with
recombinant E1 and E2 proteins produced in mammalian cells
were protected against persistent infection after homologous or
heterologous HCV challenge (16). Furthermore, cross-reacting,
broad NAb against several HCV genotypes were generated
following immunization with a recombinant HCV E1E2 vaccine
(18, 21).
The removal of the respective transmembrane domains
(TMD) of E1 and E2 can result in the secretion of truncated
forms of these proteins into the extracellular milieu (38, 39).
Vaccination with the secreted form of the E1/E2 antigens led
to an increased antibody response in mice (39, 40) as secretion
of the antigens increase their chances of capture by antigen
presenting cells (APCs), resulting in increased immunogenicity
(41–43). However, it is difficult to elicit anti-E1 responses which
have been reported to require the separation of the E1E2
heterodimer, suggesting that the E2 protein is immunodominant
or that E2 expression masks the immunogenic epitopes on E1
(18). Furthermore, a recent study using a vaccine candidate
based on chimeric hepatitis B virus (HBV)-HCV envelope
particles, showed that E1- and E2-specific antibody responses
were profoundly impaired in animals immunized with VLPs
expressing a E1E2 heterodimer compared to animals vaccinated
with VLPs expressing E1 and E2 separately (44). Additionally,
the E1- and E2-specific antibodies were able to cross-neutralize
numerous other HCV genotypes, emphasizing the significance of
including E1 and E2 as separate immunogens to induce both E1-
and E2-specific antibody response (44).
DNA-based vaccination offers a unique alternative method of
immunization. DNA vaccines can induce both CMI and antibody
responses, result in persistent expression of heterologous antigen
and elicit a memory response toward the antigen (45, 46).
Additionally, DNA vaccines are safe in humans, and are easy and
cost effective to produce on a large-scale (47). However, DNA
vaccines often induce poor immune responses in large animals
despite being effective in mice (45), and require adjuvants for
maximum effect (46). Co-administration or co-expression of
a DNA vaccine with a plasmid encoding immunomodulatory
proteins, such as interleukin (IL)-12 (48) or cytolytic adjuvants
such as perforin (49–53) represent strategies employed to boost
antigen-specific immunity following DNA vaccination.
Oligomerization is used by various proteins to increase
protein valency, structural stability and binding affinity (54).
Recently, fusion of protein antigens to a chimeric version of the
oligomerization domain from the chicken complement inhibitor
C4b-binding protein (C4 bp) (termed IMX313), was reported to
result in self-assembly into soluble heptameric structures after
expression, resulting in improved antibody responses compared
to the same dose of monomeric antigen (55–57). Furthermore,
mice vaccinated with the malaria vaccine candidate MSP119
fused to IMX313 were protected against challenge with a
lethal dose of Plasmodium yoetii parasites (55). Other reports
have shown that vaccination of mice with the Mycobacterium
tuberculosis antigen 85A fused to IMX313 in both viral vector
and DNA vaccines resulted in consistently increased CD4+ and
CD8+ T cell responses in mice and increased magnitude of
the immune response in mice and non-human primates (56).
Furthermore, a recent phase I clinical trial of a viral vector
encoding 85A-IMX313 in healthy BCG (Bacillus Calmette-
Guerin)-previously vaccinated adults revealed that the vaccine
was well-tolerated and immunogenic (58) (clinicaltrials.gov ref.
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NCT01879163). More recently a DNA vaccine, encoding a
secreted form of the HIV Tat protein fused to IMX313, elicited
anti-Tat NAb, Tat-specific CMI and protection against challenge
with a chimeric HIV, EcoHIV, in mice (59).
Therefore, the aim of this study was to examine the
immunogenicity of a DNA vaccine encoding secreted HCV E1
and/or E2 after fusion with a modified form of IMX313, namely
IMX313P. Since the adjuvanticity of IMX313 or IMX313P
requires the protein to be effectively secreted (55–57), a tissue
plasminogen activator (tPA) leader sequence was introduced
upstream of the truncated E1 or E2 proteins (sE1 or sE2)
from which the TMDs were removed. Additionally, because the
optimal approach of processing and presenting these proteins for
potent immunization is yet to be defined, the efficacy of DNA
vaccines encoding sE1 and sE2 proteins as separate immunogens
or as a single truncated sE1E2 polyprotein fused to IMX313P
was assessed in BALB/c mice after intradermal prime-boost DNA
immunizations or after boosting DNA immunized mice with
sE1E2 proteins or VLPs expressing E1E2.
MATERIALS AND METHODS
DNA Plasmid Construction
Codon-optimized genes (Gene Art, Germany) encoding gt1b
HCV E1 and E2 (GenBank accession number AF139594.2)
were used in a series of overlapping PCRs to remove the E1
and E2 TMD and introduce the signal peptide sequence of
the tissue plasminogen activator (tPA) upstream of E1 or/and
E2. These genes were inserted into pVax downstream of the
cytomegalovirus (CMV) promoter and the tPA leader sequence
to generate p-sE1, p-sE2, or p-sE1E2 (Figure 1A). Similarly, the
codon optimized IMX313P gene was introduced downstream
of the E1 and/or E2 genes to generate p-sE1-IMX313P, p-
sE2-IMX313P, or p-sE1E2-IMX313P. p-sE1E2-Histag plasmid
encoding secreted E1/E2 fused to a 6×His tag was used to express
E1 and E2 in HEK293T cells for ELISA. The bicistronic plasmid
p-CE1E2-PRF(DA), encoding full length HCV (gt1b) core, E1
and E2 proteins under the control of the CMV promoter and a
non-cytolytic version of perforin [PRF(DA)] containing a D483A
mutation (50–61) under the control of the simian virus 40 (SV40)
promoter, was used to express the native structural proteins in
HEK cells as an antigen target in immunofluorescence. DNA
constructs used in immunizations were prepared using the
Endotoxin Free Plasmid Giga Kit from Qiagen following the
manufacturer’s instructions.
Immunofluorescence
Human embryonic kidney 293T (HEK293T) cells were cultured
in 96 well plates in Dulbecco modified Eagle’s medium
(DMEM, Life Technologies) supplemented with 1% penicillin-
streptomycin (Life Technologies) and 10% fetal calf serum at
37◦C in 5% CO2. The cells were transfected with 200 ng of
DNA using Lipofectamine LTX (Life Technologies) according to
the manufacturer’s protocol. Thirty-six hours post-transfection,
the cells were fixed in 4% paraformaldehyde then permeabilized
with 100% methanol. The cells were then incubated with the
appropriate primary antibody at 37◦C for 2–4 h at 37◦C or
overnight at 4◦C followed by the addition of the appropriate
fluorophore-conjugated secondary antibody for 1 h at 37◦C
in the dark. Primary antibodies used include mouse anti-E1
(MyBiosource, Cat. No. MBS310203), goat anti-E2 (Virostat,
Cat. No. 2851), pooled sera collected from vaccinated mice or
human MAb (kindly supplied by Heidi Drummer). Secondary
antibodies were Alexa Fluor (AF) 488-conjugated anti-mouse,
AF488-conjugated anti-human and AF555-conjugated anti-
goat (all from Invitrogen). Nuclei were stained with Hoechst
33342 (Life Technologies). Cells were visualized by fluorescence
microscopy (Zeiss LSM-700) and the data digitized using the Zen
software (Zeiss).
Western Blotting Analysis
To confirm E1/E2 expression, supernatant fluids were harvested
from HEK293T cells transfected with p-sE1, p-sE2, p-sE1E2,
p-sE1-IMX313P, p-sE2-IMX313P, or p-sE1E2-IMX313P and
50 µg of protein was analyzed for antigen expression in
10–12% (v/v) SDS-PAGE under reducing or non-reducing
conditions as described previously (55–57, 59, 62). Mouse anti-
E1 (MyBiosource, Cat. No. MBS310203) and human anti-E2
MAb HCV1 were used as primary antibodies to detect E1 and
E2 expression followed by followed by anti-mouse-AF488 and
anti-human AF555 (both from Invitrogen). The membrane was
imaged using the LAS4000 digital imaging system (Fujifilm)
and the resultant images were overlaid using ImageJ software
(National Institutes of Health, USA) to obtain colocalization data.
Protein Purification
After transfection of HEK293T cells with p-sE1E2-Histag, the
histidine-tagged recombinant sE1E2 complex was purified by
affinity chromatography from the cell culture medium using a
Nickel-agarose column (Ni-NTA column; Qiagen) according to
the manufacturer’s recommendations. Briefly, the cell culture
fluids were collected and clarified 48 h post-transfection, followed
by ultrafiltration through a 70,000-molecular-weight cut-off filter
(Amicon). The concentrated proteins were applied to the Ni-
NTA column. Following three washes with buffer B (30mM
imidazole, pH 8), purified protein was eluted with 300mM
imidazole elution buffer (pH 8). Purified sE1E2 proteins were
quantified using the Bradford protein assay (Bio-Rad) and
analyzed by PAGE and Western blot.
Animal Immunizations
Six to eight weeks old female BALB/c mice (n = 7 per group)
were obtained from University of Adelaide Laboratory Animal
Services and maintained under PC2 conditions in individually
ventilated HEPA-filtered cages (Aero 80; Tecniplast, Italy) at the
Queen Elizabeth Hospital animal facility. All experiments were
conducted according to guidelines and protocols approved by the
University of Adelaide Animal Ethics Committee (AEC; approval
numbers: M-2018-30 and M-2015-135) and SA Pathology AEC
(approval numbers: 2–18 and 29–15). For immunizations, mice
were anesthetized with isoflurane and received 50 µg of total
DNA per dose per animal of endotoxin-free DNA injected
intradermally (ID) as described previously (51, 52). This is
because the ID route is more effective than intramuscular or
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FIGURE 1 | Construction and validation of DNA vaccine constructs. (A) Schematic diagram of the DNA constructs used in the study. DNA vaccines encoding sE1,
sE2, or sE1E2 were produced by fusion to an N-terminal signal peptide, tPA, including one construct with a C-terminal hexahistidine (His6) tag. Constructs encoding
secreted envelope proteins fused to the IMX313P domain were also generated. The numbering coincides with the amino acid positions in the polyprotein of the HCV
genotype 1b strain (GenBank accession number AF139594.2). DNA plasmid sizes are shown on the right. Western blot analysis of HCV proteins in concentrated cell
culture media harvested from HEK293T cells transfected with DNA constructs encoding secreted envelope with or without IMX313P under (B) reducing and (C)
non-reducing conditions, and probed with mouse anti-E1 or human anti-E2 MAb HCV1 primary antibodies, followed by mouse anti-AF488 (green signal) or human
anti-AF555 (red signal). The yellow signal represents the co-detection of E1 and E2. Molecular weight (MW) markers are indicated on the left in kilodaltons and HCV
protein oligomers are indicated on the right. pVax-transfected cells represent controls to show non-specific bands. (D) Immunofluorescence analysis HEK293T cells
transfected with the different DNA vaccines and controls were stained with human MAbs. Scale bar = 50µm.
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even subcutaneous DNA delivery [reviewed in (63)], likely
due to a higher proportion of dendritic cells (DC) in the
dermis/subdermis than other anatomical sites (63, 64). The DNA
vaccines were administered 5–6 times at 3-weeks intervals.
ELISpot Analysis
The frequency of mouse IFN-γ secreting E1 or E2-specific T
cells was measured by ELISpot assay as described previously (49,
51). Briefly, red blood cell-depleted splenocytes from vaccinated
mice, at 5 × 105 cells per well, were stimulated with 4µg/ml
of either E1 or E2 peptides (HCV genotype 1b J4 Peptides, E1
catalog number: NR3738, E2 catalog number: NR3739, provided
by the National Institutes for Health Biodefense and Emerging
Infectious Research Resources Repository (NIAID), Bethesda,
MD) for 36 h at 37◦C. The E1 peptides consisted of one pool
of 28 overlapping 15–19 mer peptides spanning the entire E1
protein. The E2 peptides were divided into 2 pools containing
28 (E21−186) and 27 (E2176−363) overlapping 15–19 mer
peptides, respectively. Secreted IFN-γ was detected using anti-
mouse IFN-γ-biotin (clone R4-6A2; MabTech), streptavidin-AP,
and SigmaFast BCIP/NBT (Sigma). An ELIspot reader (AID
Germany) was used to count the spots. To generate the number
of specific spot-forming units (SFU) per 106 cells, the number
of spots in unstimulated splenocytes was subtracted from the
number of spots in the peptide-stimulated splenocytes. Data are
presented as mean ± the standard error of the mean (SEM).
Responses to E2 peptide pool 1 and 2 were combined to give a
cumulative value for E2.
ELISA for HCV E1/E2 Specific IgG
Nunc MaxiSorp ELISA plates were coated with 2 µg Ni-NTA
Agarose chromatography purified sE1E2 proteins in 50 µl 0.1M
sodium bicarbonate buffer overnight at 4◦C. The wells were then
blocked with 2.5% BSA/PBS (blocking buffer) for 2 h at 37◦C and
washed four times with 0.01% Tween 20 in PBS (PBS-T). Mouse
sera were serially diluted in blocking buffer then added to the
plate overnight at 4◦C, followed by four washes in PBS-T. The
Secondary antibody, goat anti-mouse immunoglobulin (IgG)
HRP (Invitrogen), was diluted 1: 3,000 in blocking buffer and
added to the plate for 1 h at 37◦C, followed by four washes with
PBS-T. 1-Step
TM
Ultra TMB-ELISA substrate (ThermoFisher
Scientific) was added and the reaction was stopped with 2M
sulfuric acid. The absorbance was measured at 450 nm using a
FLUOstar OPTIMA plate reader (BMG LabTech). HCV E1 and
E2-specific IgG endpoint titers were determined as the highest
reciprocal dilution of serumwith an optical density (OD) reading
above the cut-off, set as 2 standard deviations (SD) above the
mean OD of serum samples from pVax-vaccinated mice.
Peptide ELISA for Mapping of E1 and E2
Epitopes
HCV peptide ELISA was performed using overlapping peptides
representing the E1 or E2 region of the HCV J4 isolate
(gt1b) as described previously (39, 65). The peptides consisted
of 18-mers with an overlap of 11 amino acids covering the
E1 or E2 HCV glycoprotein region (BEI Resources, NIAID,
Bethesda, MD). Briefly, plates were coated with 5µg/ml of
4–5 pooled peptides per well, blocked with 4% BSA/PBS,
incubated with mouse sera (1:50 dilution) for 4 h at 37◦C
and antibody binding was assessed using an ELISA setup as
described above.
HCV Neutralization of Binding Assay
The HCV neutralization assay to measure the inhibition of
HCV VLP binding and entry into Huh7 cells was performed
as described previously (66, 67). Briefly, 50 ng of fluorescein
isothiocyanate (FITC) labeled gt1b HCV-VLPs were incubated
with serial dilutions of sera from vaccinated or non-vaccinated
mice for 1 h at 37◦C. The complex was then allowed to
bind to Huh 7 cells for 1 h at 4◦C, then incubated at
37◦C for 1 h to promote entry. The cells were then washed
to remove unbound HCV-VLPs and fixed in BD Cytofix
(Becton Dickinson, USA). Inhibition of VLP binding/entry
was determined by flow cytometry using FACS Calibur flow
cytometer (Becton Dickinson) and analyzed using WinMDI II
software. As a positive control, inhibition of entry of FITC-
HCV VLPs into Huh7 cells was also determined using an anti-
CD81 antibody (Abcam). Normal mouse serum was used as a
negative control.
HCVpp Production and Neutralization
Assay
Retroviral HCV pseudoparticles (HCVpps) were prepared and
the neutralization assay performed as described previously
(68). Briefly, heterologous HCVpp harboring HCV envelope
glycoproteins representing the 6 main HCV genotypes
including H77.20 (GenBank accession AF011751), UKN1A20.8
(EU155192), UKN1B5.23 (AY734976), UKN2A1.2 (AY734977),
UKN2A2.4 (AY734979), UKN2B1.1 (AY734982), UKN2B2.8
(AY734983), UKN3A1.28 (AY734984), UKN3A1.9 (AY734985),
UKN3A13.6 (AY894683), UKN4.11.1 (AY734986), UKN4.21.16
(AY734987), UKN5.14.4 (AY785283), UKN6.5.8 (EF427671),
and UKN6.5.340 (AY736194) were titrated to standardize the
infectivity of all HCVpp to be 5 to 20-fold more infectious than
mock pseudoparticles lacking HCV E1/E2.Mouse serum samples
diluted at 1:5 or 1:10 were incubated with equivalent amounts
of the titrated HCVpp for 1 h at 37◦C and added to Huh7.5
cells (Apath, New York, NY, USA). The cells were lysed after
72 h and Bright Glo reagent (Promega) was added, followed by
luminescence measurement on a CLARIOstar microplate reader
(BMG Labtech). The percentage neutralization was calculated as
(1 – RLUtest mouse serum÷RLUpre−immune mouse serum)× 100.
Statistical Analyses
Data are presented as means ± the standard errors of the
mean (SEM). Statistical analysis was performed using unpaired
Mann-Whitney tests, with ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001,
and ∗∗∗∗P ≤ 0.0001 considered significant. The analysis was
performed using GraphPad Prism 7 for Windows (GraphPad
Software, La Jolla, CA).
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RESULTS
Secreted HCV-E1/E2 Proteins Form
Oligomers Following Fusion to IMX313P
DNA vaccines, each encoding a different form of sE1 and/or
sE2, were constructed in pVAX: p-sE1, p-sE2, p-sE1E2, p-sE1-
IMX313P, p-sE2-IMX313P, and p-sE1E2-IMX313P (Figure 1A).
To confirm expression, secretion and oligomerization of E1 and
E2, cell culture supernatant fluids were collected from transfected
HEK293 cells and western blot analysis was performed under
reducing (Figure 1B) and non-reducing (Figure 1C) conditions.
The protein expressed from the p-sE1E2-Histag construct that
was used to coat ELISA plates was purified using a Nickel-agarose
column before western blot analysis (Figure 1B).
Oligomers of sE1- and/or sE2-IMX313P were only detectable
in non-reducing conditions and accordingly, under reducing
conditions, proteins that migrated as monomers of 37 kDa
for E1 and ∼68 kDa for E2 were detected using E1 and
E2-specific antibodies (Figure 1B). As the coding sequences
for the E1 and E2 TMDs were removed from the DNA
constructs and the proteins no longer contained a canonical
protease cleavage site, the sE1E2 proteins were not cleaved into
E1 and E2 but migrated as a sE1E2 complex of ∼80 kDa
(Figure 1B). The sE1 and/or E2 proteins fused to IMX313P
fusion proteins migrated under non-reducing conditions as a
broad oligomeric band ofmolecular mass>250 kDa (Figure 1C).
As expected, oligomers were not detected in supernatant fluids
from cells transfected with p-sE1, p-sE2, p-sE1E2, or p-sE1E2-
Histag (Figure 1C). These proteinsmigrated under non-reducing
conditions as monomers. No HCV-specific bands were detected
from proteins isolated from cells transfected with the pVax
control. The expression of E1 and E2 was also assessed by
immunofluorescence (Supplementary Figure S1).
Folding of these different forms of the HCV envelope proteins
was assessed by a set of human MAbs including HC33.1
(69), HCV1 (70), AR3C (71), 2A12 (72), and HC84.27 (73)
(kindly provided by Heidi Drummer), capable of binding to
the E2 protein (Figure 1D). These MAbs, except 2A12, block
the interaction of E2 with CD81 by binding to the regions
of E2 that form the CD81 receptor binding site (35, 69–73)
and demonstrated that the respective neutralizing epitopes were
exposed following protein expression. As expected, these MAbs
were unable to bind to cells transfected with constructs encoding
E1 only (Figure 1D). These results demonstrate that fusion of
IMX313P to sE1, sE2, or sE1E2 resulted in oligomerization of
each of these proteins and confirmed that the different forms
of the envelope proteins encoded in pVax were expressed and
detected as predicted.
DNA Vaccines Encoding E1E2 Fused to
IMX313P Generate Significant T-Cell
Immune Responses in vivo
Groups of mice were vaccinated with (i) p-sE1 + pVax, (ii) p-
sE2 + pVax, (iii) p-sE1 + p-sE2, (iv) p-sE1-IMX313P + pVax,
(v) p-sE2-IMX313P + pVax, (vi) p-sE1E2-IMX313P + pVax, or
(vii) p-sE1-IMX313P + p-sE2-IMX313P. pVax only vaccinated
mice served as a mock control and pVax was included in some
vaccine cocktail regimens to ensure that all animals received an
equimolar amount of DNA.
Interferon (IFN)-γ enzyme-linked immunospot (ELISpot)
assay was conducted to assess the induction of cellular immune
responses against the E1 and E2 proteins. Four weeks after
vaccination, splenocytes were harvested and stimulated with E1
and E2-specific peptides. Mice vaccinated with p-sE1, p-sE2, or
p-sE1E2 resulted in the lowest IFN-γ spot forming unit (SFU)
responses (Figure 2A), while mice vaccinated with the constructs
encoding sE1/sE2 fused to IMX313P induced the highest IFNγ
SFU responses (Figure 2B). Although the p-sE1-IMX313P +
pVax group elicited minor responses to E2 peptides, this was
not significant and can be assumed to represent background.
As the data in Figures 2A,B were obtained in independent
experiments, we pooled the data from these two experiments
and calculated the IFN-γ SFU in each animal vaccinated with
pVax encoding E1 and/or E2 as the fold increase over the
mean responses observed in the respective pVax control group
(Figure 2C). This analysis revealed that vaccination with p-
sE1E2-IMX313P (+ pVax) elicited the greatest CMI responses to
E1 and E2. In general, fusion of IMX313P to sE1, sE2, or sE1E2
in DNA vaccines enhanced the frequency of IFN-γ secreting
T cells compared to the respective DNA vaccine counterparts
lacking IMX313P (Figure 2C). However, statistically significant
differences were only obtained when comparisons were made
between p-sE1E2 + pVax vs. p-sE1E2-IMX313P + pVax
and p-sE1 + psE2 vs. p-sE1-IMX313P + p-sE2-IMX313P
(Figure 2C). Overall, the results shown in Figure 2 revealed
that vaccination with a DNA construct encoding sE1 and/or
sE2 proteins fused to the IMX313P domain induced superior
cell mediated immune responses with the most immunogenic
vaccine being p-sE1E2-IMX313P.
Vaccination With DNA Encoding sE1
and/or sE2 With IMX313P Induces Superior
Antibody Responses in Mice
To determine the antibody responses elicited following
vaccination with the different DNA vaccines, mouse serum
was collected at intervals after each vaccination and analyzed
for E1E2-specific antibodies by ELISA using affinity purified
E1E2. As we showed that this E1E2 target contained both E1
and E2 proteins (Figures 1B,C), antibody responses detected
by ELISA are referred to as anti-E1E2 responses. As shown
in Figures 3A,B, the antibody levels peaked and plateaued
following the 4th immunization for all groups although the
antibody levels in the groups exposed to IMX313P were only
modestly above those elicited by vaccines lacking IMX313P.
However, vaccination with DNA constructs encoding E1
induced minimal levels of E1E2-specific responses. The anti-
E1E2 antibody levels were higher in groups vaccinated with
DNA encoding secreted envelope proteins and IMX313P
compared to pVax, with the exception of mice vaccinated with
p-sE1-IMX313P + pVax (Figure 3C). The end point titers for
anti-E1E2 antibodies determined after the 4th immunization
also support this trend and showed that vaccination with
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FIGURE 2 | IMX313P adjuvanted DNA vaccination elicits higher HCV-specific cellular immune responses in BALB/C mice. Mice were vaccinated six times at 3-week
intervals with DNA constructs encoding (A) sE1, sE2, sE1E2, (B) sE1 and/or sE2 fused to IMX313P. Splenocytes were harvested 28 days after the final vaccination,
re-stimulated in duplicate with overlapping HCV peptide pools representing gt1b E1 and E2 proteins and IFN-γ secretion was measured by ELISpot assay. The data
are expressed as mean (n = 7) SFU per 106 cells responses to different peptide pools and presented as the mean ± SEM per group. The number of SFU in
unstimulated cells was subtracted from the number in cells stimulated with peptides to generate the net HCV response. (C) ELISpot data plotted as mean SFU fold
increase (+SEM) relative to pVax control for comparison. Significance tested against respective controls. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; and ****p ≤ 0.0001
(Mann-Whitney test non-parametric t-test).
p-sE1-IMX313P + p-sE2-IMX313P resulted in the highest
average titer of 1/1749, followed by p-sE2-IMX313P-vaccinated
mice (average titer 1/1707), and p-sE1E2-IMX313P (average
titer 1/1346). By comparison, vaccination with p-sE1E2, p-sE2
or p-sE1 induced titers of 1/113, 1/67, and 1/18, respectively
(Figure 3C). Vaccination with p-sE1 or p-sE1-IMX313P induced
the lowest antibody titers (average titer <1/10; Figure 3C).
Additionally, antibodies generated following vaccination with
these DNA constructs were also capable of binding to the
full-length E1E2 heterodimer as shown by immunofluorescence
analysis (Figure 3D). Collectively, the data indicate that DNA
vaccines encoding secreted envelope proteins and IMX313P can
elicit robust HCV E1E2-specific antibody responses and that
these responses were superior to those induced by immunization
with DNA vaccines encoding secreted envelope proteins only.
E1E2 Protein Boost Increases Anti-E1E2
Responses in Mice Vaccinated With DNA
Vaccines Encoding Secreted Envelope
Proteins and IMX313P
The above studies suggest that the p-sE1-IMX313P + p-sE2-
IMX313P and p-sE1E2-IMX313P vaccination regimens were the
most robust in eliciting CMI and antibodies against E1E2. Next,
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FIGURE 3 | IMX313P adjuvanted DNA vaccination also induces higher HCV-specific antibody responses. Serum from mice vaccinated with (A) p-sE1, p-sE2, or
p-sE1E2 or (B) p-sE1-IMX313P, p-sE2-IMX313P, or p-sE1E2-IMX313P was diluted (1/50) and anti-E1E2-specific antibodies were measured by ELISA at the indicated
(Continued)
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FIGURE 3 | time points. The arrows indicate when the vaccines were administered. (C) sE1E2-specific serum IgG titers 4 weeks after the final immunization (week
19). Titers are expressed as the reciprocal of the serum dilution and plotted as Log10. The data represent mean responses in each group (n = 7) ± SEM. **p < 0.01,
and ***p < 0.001 (Mann-Whitney non-parametric t-test). (D) Immunofluorescent analysis of antibodies specific for full-length E1 and E2 proteins in immune sera.
HEK293T cells were transfected with a bicistronic construct, pVax-coreE1E2-PRF(DA) encoding full length gt1b core, E1 and E2 proteins and PRF(DA) (a non-cytolytic
version of perforin containing a D483A mutation) (50–61); and pooled sera from immunized-mice were used as the primary antibody at a 1:50 dilution. (E) A schematic
diagram of the pVax-coreE1E2-PRF(DA) DNA construct.
we evaluated whether the immunogenicity of these vaccination
regimens could be improved following booster immunizations
with sE1E2 protein or VLPs expressing E1E2 (Figures 4A,B).
The purified sE1E2 poly-His-tagged fusion protein described
above constituted the E1E2 protein boost. The production and
purification of the genotype 1 (gt1) HCV VLPs have been
described elsewhere (66, 67). As shown above in Figures 3A,B,
the antibody response plateau was reached following four DNA
vaccinations, therefore mice were vaccinated with four doses
of p-sE1-IMX313P + p-sE2-IMX313P or p-sE1E2-IMX313P,
before receiving a boost with DNA, sE1E2 protein or the
VLPs (Figure 4B).
To compare CMI elicited by the different regimens, the
IFN-γ ELISpot assay was performed using E1 and E2 peptide
pools to stimulate the splenocytes (Figure 4C). As shown in
Figure 4C, comparable IFN-γ responses significantly above
the pVax control were observed after all vaccination regimens
(Groups 2–7) which encoded secreted envelope immunogens.
However, p-sE1-IMX313P + p-sE2-IMX313P prime/E1E2
protein induced the highest responses, 178.5 SFU/106 cells,
following stimulation with E1 peptides and 579.3 SFU/106 cells
following stimulation with E2 peptides (Figure 4C), although
these were not statically significant compared to the other
vaccine groups.
To determine the antibody responses, mouse serum samples
were collected and analyzed for E1E2-specific antibodies by
ELISA. As previously observed, the antibody levels peaked and
plateaued following the 4th immunization in all groups except
for the pVax group (Group 1) which as expected did not elicit
specific antibodies to E1E2 (Figure 4D). Vaccination with p-
sE1E2-IMX313P followed by a boost with E1E2 protein (Group
5) resulted in the highest E1E2-specific antibody levels, although
these levels were similar to those observed for the p-sE1-
IMX313P + p-sE2-IMX313P prime/ E1E2 protein boost (Group
4) followed by the p-sE2-IMX313P prime/ HCV VLP boost
(Group 7) (Figure 4D).
The antibody titers were measured 4 weeks post the
final vaccination and showed that the DNA prime/E1E2
protein boost vaccination regimen induced significantly higher
titers compared to boosting with DNA or the HCV VLPs
(Figure 4E). Boosting with the sE1E2 proteins following
immunization with p-sE1E2-IMX313P or p-sE1-IMX313P +
p-sE2-IMX313P resulted in the highest anti-E1E2 antibody
responses (average titer of 1/4,678 and 1/2,004, respectively)
(Figure 4E). This was followed by responses from animals
vaccinated with p-sE1E2-IMX313P and boosted with VLPs
(average titer: 1/1,386) or p-sE1E2-IMX313P DNA (average
titer: 1/768). Animals vaccinated with p-sE1-IMX313P + p-
sE2-IMX313P and boosted with the same DNA or HCV VLPs
generated similar anti-E1E2 responses with an average titer
of 1/446 (Figure 4E). These antibodies were also capable of
binding to full length E1E2 as shown by immunofluorescence
(Figure 4F). Collectively, the data indicate that recombinant
E1E2 protein provides a superior boost compared to DNA or
HCV VLPs and is capable of enhancing HCV E1E2-specific
antibody responses in p-sE1E2-IMX313P or p-sE1-IMX313P +
p-sE2-IMX313P-vaccinated mice.
Prime-Boost Vaccinations With Vaccines
Encoding or Expressing Monomeric or
Oligomerized Secreted Envelope Proteins
Elicit Antibodies That Recognize E1 and E2
Epitopes
Overlapping peptide ELISA was conducted to map the reactivity
of serum antibodies to continuous and discontinuous epitopes
on E1E2. ELISA plates were coated with E1 or E2 overlapping
peptides to assess the serum antibody responses to continuous
epitopes (Figure 5). There was little difference in reactivity to
the E1 peptides between all the immunized groups, although
sera from animals immunized with the p-sE1E2-IMX313P DNA
prime/ E1E2 protein boost regimen or the DNA prime/ HCV
VLP boost regimen showed a slightly higher reactivity compared
to other immunized groups (Figure 5A). In contrast, the sera
showed greater reactivity against E2 and reacted with peptides
spanning aa 412–522 and aa 541–713 (Figure 5B), while the
highest reactivity was seen toward aa 481–522, 607–649, and
639–680. All vaccinated groups showed limited reactivity toward
hypervariable region (HVR) 1, aa 384–411, and the TMD,
aa 716–747, but some reactivity against HVR2, aa 460–485,
and aa 570–580 representing the intergenotypic variable region
(igVR; also known as HVR3) (Figure 5B). As the TMD was
not included in the vaccine immunogen, the level of reactivity
against peptides representing this region can be assumed to
represent background.
A DNA Boost Induced Cross-Neutralizing
Antibodies in Mice Vaccinated With
p-sE1/sE2-IMX313P
To assess the neutralizing ability of the antibodies generated by
the different vaccination regimens, we investigated the ability of
the sera to inhibit binding of genotype 1b HCV VLPs to Huh7
cells. Fluorescent-labeled HCV VLPs were incubated with the
serum at 1/5 and 1/25 dilutions, and the binding of the VLPs
to Huh7 cells was monitored by flow cytometry as described
(66, 67). Incubation of the HCV VLPs with PBS (VLP only)
or normal mouse serum (NMS; Sigma) resulted in minimal
inhibition of HCVVLP binding to hepatocytes (8%), whereas the
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FIGURE 4 | Boosting with recombinant sE1E2 protein augments the cellular and humoral immunity elicited in mice previously vaccinated with IMX313P adjuvanted
DNA vaccines encoding secreted envelope proteins. (A) Vaccination groups and (B) immunization schedule of animals. The arrows indicate when the vaccines were
administered. Female BALB/C mice (n = 7/group) were vaccinated at 3 weeks intervals via the ID route with 50 µg of p-sE1E2-IMX313P or p-sE1-IMX313P +
p-sE2-IMX313P and boosted with DNA or E1E2 recombinant protein or HCV VLPs 3 weeks later. pVax was included in the vaccine cocktail to ensure that all animals
were vaccinated with an equimolar amount of DNA. (C) IFN-γ ELISpot assay to examine E1- or E2-specific CMI in splenocytes stimulated with E1- or E2-peptides for
36 h. (D) Anti-E1E2-specific antibodies levels measured by ELISA (at 1:50 dilution) at the indicated time points. (E) sE1E2-specific serum IgG 4 weeks after the final
immunization. Titers are expressed as the reciprocal of the dilution factor of the serum and plotted as Log10. The data represent mean responses in each group (n =
7) ± SEM. *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001; and ****p ≤ 0.0001 (Mann-Whitney non-parametric t-test). (F) Immunofluorescence analysis of antibodies specific for
full-length E1 and E2 proteins in immune sera. HEK293T were transfected with pVax-coreE1E2 encoding full length E1E2 proteins and pooled sera from mice
immunized were used as the primary antibody at a 1:50 dilution.
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FIGURE 5 | Reactivity of sera from DNA prime/DNA boost, DNA prime/E1E2 protein boost or DNA prime/HCV VLP boost-immunized animals to E1E2 peptides.
Serum antibody responses specific to a library of overlapping (A) E1 or (B) E2 peptides, supplied by BEI Resources, in ELISA 4 weeks after the last vaccination.
Serum from vaccinated mice was diluted (1/50) and added to wells coated with HCV peptides. Values represent mean responses in each group (n = 7) + SEM. Data
are representative of 3 independent experiments performed in duplicate.
addition of anti-CD81 antibodies on the other hand (Figure 6),
inhibited VLP binding to Huh7 cells by >90% confirming that
these particles use CD81 to bind to target cells, in a similar
manner to HCV (74, 75).
Dose-dependent inhibition of binding of the HCV VLPs
by serum from the vaccinated mice was observed across all
vaccination groups although most of the samples showed
some non-specific inhibition at a 1/5 dilution (data not
shown). At a 1/25 dilution which was considered to represent
specific inhibition, the highest neutralization of HCV VLPs
binding to Huh7 cells was detected in group 2 with 71.5%
neutralization (Figure 6). However, the neutralization levels
were comparable between groups 2–5. Surprisingly the lowest
inhibitions were observed in groups 6 and 7 with 41% and
30.5% neutralization, respectively (Figure 6). Although these
results were not statistically significant, they suggest that
antibodies generated against HCV genotype 1b E1/E2 proteins
possess neutralizing properties and could neutralize the binding
of genotype 1b VLPs to target cells, and that homologous
DNA prime-boost vaccination with p-sE1-IMX313P + p-sE2-
IMX313P (group 2) resulted in the highest neutralization activity
to prevent HCV VLP binding/entry into hepatocytes.
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FIGURE 6 | p-sE1/sE2-IMX313P DNA prime/DNA boost vaccination elicits anti-E1E2 antibodies with HCV VLP neutralizing activity. Neutralization of VLP binding was
determined by pre-incubating fluorescent-labeled VLPs with pooled serum from vaccinated mice followed by incubation with Huh7 cells. The cells were then
harvested, and fluorescence levels analyzed by flow cytometry. All bar graphs show the percentage reduction in VLP entry following incubation with mouse sera at
1:25 dilution. The percentage values are indicated at the top of each bar. Y-axis depicts the percentage inhibition of binding of HCV-LPs to Huh7 cells; X-axis
represents the different vaccine or control groups.
Additionally, the mouse sera were tested for their capacity
to neutralize HCVpp pseudotyped with envelope proteins from
different genotypes including genotypes 1a, 1b, 2a, 2b, 3a, 4, 5, or
6 (Table 1). Although a range of serum dilutions was tested, only
the 1/5 and 1/10 dilutions showed evidence of neutralization.
Essentially, all anti-E1- and/or anti-E2- antibody positive samples
showed dose-dependent cross-neutralizing properties in vitro
against the different HCVpp genotypes and showed a minimum
of 70% neutralization (at 1/5 dilution) against HCVpp from
genotypes 1a, 1b, 2a, 3a, and 4 (Table 1). However, serum from
these animals (groups 2–7) showed lower neutralizing activity
against genotypes 2a, 2b, 4, and 6, and were less efficient at
neutralizing HCVpp from genotypes 5 and 6 (Table 1). Serum
from mice vaccinated with pVax generally showed minimum
neutralization of the HCVpp except for pseudotyped particles
from a few genotypes with the 1/5 serum dilution.
Similar to the results observed in Figure 6, vaccination with
the homologous DNA prime/DNA boost regimen induced the
highest NAb responses (Groups 2 and 3, Table 1). Antibodies
generated after vaccination with p-sE1E2-IMX313P were the
most effective at cross-neutralizing the HCVpp with >50%
neutralization at 1/5 serum dilution across all genotypes (Group
3, Table 1). The cross-neutralizing properties of antibodies
generated following vaccination with the DNA prime/ VLPs
boost were generally similar to those produced by vaccination
with the DNA prime/ E1E2 protein boost, although the latter
elicited higher antibody titers. However, at 1/10 dilution, the sera
fromDNA prime/VLPs boost vaccinated mice were generally less
efficient at neutralizing the HCVpp compared to sera from mice
that received the DNA prime/E1E2 protein boost regimen. In
contrast, the antibodies generated by the DNA prime/DNA boost
regimen still showed high HCVpp cross-neutralizing activity at
1/10 dilution.
Overall, the data show that vaccination with a DNA vaccine
encoding a secreted, oligomerized form of E1E2 can significantly
augment E1E2-specific immune responses, and importantly
generate antibodies with cross-neutralizing activity.
DISCUSSION
An effective vaccine is the optimal long-term, cost-effective
solution to combat HCV globally. Studies in humans and
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non-human primates have provided insight into the possible
correlates of protection, although the actual correlates remain
poorly understood. It is generally accepted that an effective HCV
vaccine should at least induce NAb targeting envelope proteins,
but it is likely that CMI against the non-structural proteins
will also be required. HCV envelope proteins are involved in
essential initial steps in the virus replication cycle including
viral attachment/entry or membrane fusion. Therefore, E1 and
E2 represent significant vaccine immunogens and have been a
major focus of various HCV vaccine development studies (17,
18, 66, 76, 77). Consequently, these proteins were the focus of
the vaccine strategies described in this study. Previous reports
have demonstrated that E1 and E2 glycoproteins expressed on
the cell surface are more immunogenic than the wild-type
antigens (41, 78) and secreted E1E2 proteins have also been
shown to be significantly more immunogenic in mice (39).
Antigen oligomerization has also been shown to improve vaccine
immunogenicity (55–57). The work presented in this study aimed
to develop a DNA vaccine encoding truncated E1 and E2 fused
with the oligomerization domain of a chimeric C4 binding
protein, IMX313P, that results in the production of secreted,
oligomerized forms of the proteins. The immunogenicity of
DNA vaccines encoding E1 and/or E2 glycoproteins as separate
immunogens or as a single E1E2 polyprotein was assessed
in mice.
While oligomerization may be an important element, the
mechanism by which the C4b-p enhances immunogenicity
is still not well-understood (55, 62). Therefore, in addition
to oligomerization, other factors such as increased half-
life, improved antigen uptake, and/or prolonged antigen
processing could be involved in the enhancement of the E1/E2-
specfic responses.
All groups immunized with the HCV DNA vaccines
encoding E1E2 heptamers elicited significant levels of
anti-E1E2 antibodies. This may be the result of increased
capture and processing of the heptamers by both local and
distal APCs, consequently increasing the immunogenicity
of the E1E2 antigens (41, 55, 57, 79). Moreover, these
antibodies were also able to recognize E1E2 proteins in
their native (presumably heterodimeric) form as determined
by immunofluorescence analysis of cells transfected with a
DNA construct encoding the full-length coreE1E2 polyprotein
(80, 81). However, only limited anti-E1-specific antibody
responses were generated, in accordance with previous findings
(18, 39, 43) suggesting that the observed antibody responses
comprised mainly of anti-E2 antibodies. Nevertheless, the
antibody titers generated by vaccination with E2-encoding
constructs were comparable to those reported in the
literature (66, 77, 82).
In addition to strong humoral responses, robust CMI
responses have been reported to be critical for clearance of
HCV in humans and chimpanzees during acute infection (83–
86). Fusion of the envelope proteins to IMX313P resulted in
superior E1 and/or E2-specific antibody and CMI responses
compared to their monomeric counterparts. A robust CD8+ T
cell response with IFN-γ+ production has also been associated
with spontaneous clearance of HCV, and the impairment of this
response is a characteristic feature of persistent infection (30, 85,
87–89). All groups immunized with the DNA vaccines encoding
E1E2 heptamers induced significant IFN-γ responses compared
to animals immunized with the monomeric DNA constructs as
determined by ELISpot. The number of SFUs detected in the
E1/E2-specific ELISpot reported in this study compared favorably
with those reported in other studies using viral vectors (76, 77,
90), DNA (91), or VLPs (67, 91).
A DNA prime-protein boost strategy is a promising method
to increase the effectiveness of DNA immunization (92).
Vaccination with the DNA prime/DNA, E1E2 protein, or VLP
boost vaccination regimens resulted in the induction of high
levels of E1E2-specific antibody- and CMI- responses. Among
the three immunization strategies, boosting with recombinant
E1E2 protein induced the highest serum IgG levels. Thus,
the sE1/sE2-IMX313P DNA prime/E1E2 recombinant protein
boost vaccine strategy is consistent with current immunization
regimens involving priming with DNA followed by boosting
with viral vectors or a recombinant protein that have been
favored to induce protective immune responses to many diseases,
such as HCV, HIV and malaria (93, 94). Serum antibody
characterization revealed that the hyperimmune sera showed
greater reactivity toward epitopes located in the ectodomain of
E2. The E2 HVR1 (aa 384–410) is an immunodominant region
that has been reported to be involved in viral escape in infected
chimpanzees and humans (95, 96). However, the mouse sera
showed little reactivity against this region, similar to observation
from previous reports (39, 41, 42), perhaps reflecting the nature
of the heptamer.
To date, a majority of all effective viral vaccines work through
the generation of NAb, typically by targeting viral envelope
proteins (97). For HCV, complete neutralization of incoming
virions is difficult to achieve as the virus can be transmitted
as free virions or associated with different lipoproteins and
immunoglobulins (98, 99). Additionally, the presence of a
quasispecies with variable epitopes in the virus population
is likely to contribute to evasion of the humoral response.
Nevertheless, neutralization of a proportion of incoming HCV
virions might lead to a reduced viral load allowing the
timely development of CMI, promoting viral clearance. The
neutralization assay (Table 1) data suggested that vaccination
with DNA prime/DNA boost, notably p-sE1E2-IMX313P,
induced the highest cross-NAb responses while vaccination with
DNA prime/E1E2 protein boost or DNA prime/VLP boost
regimens generally induced lower inhibition of binding of HCV
VLPs to Huh7 cells as well as HCVpp neutralization. These
results contradict previous findings which demonstrated that
immunization with HCVVLPs induced HCV-specific NAb, since
the envelope proteins are presented on the surface of VLPs in
their correct conformation during immunization (66, 67). Our
results also suggest that, despite achieving a plateau of antibody
responses following four DNA vaccinations, an additional DNA
vaccination was necessary to induce significant NAb, most
likely reflecting the poor immunogenicity of the HCV envelope
proteins. Furthermore, the single dose of VLPs administered in
this study might have been inadequate as previous studies have
demonstrated that two or more doses of VLPs are necessary to
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induce NAb (66). Therefore, it is possible that additional boosting
with the VLPs or E1E2 proteins may have induced even higher
NAb. Nevertheless, the neutralization levels reported in this study
compared well with previous studies (39, 44, 66, 67, 91) at similar
serum concentrations.
The novel p-sE1/sE2-IMX313P DNA vaccine constructs
described in this study represent an attractive candidate for a
HCV vaccine that could be readily scaled up. A recombinant
HCV E1E2 glycoprotein (genotype 1a) vaccine was previously
reported to decrease the carrier rate in vaccinated chimpanzees
and induce protective immune responses in some persons
following homologous and heterologous gt1a virus challenge (16,
100). Furthermore, other E1E2 candidate vaccines demonstrated
broad NAb responses in immunized human volunteers (22,
101, 102). Secreted forms of E2 can be generated using various
cell lines including mammalian and insect cells and is the
focus of the development of a humoral HCV vaccine (103,
104). However, cross-neutralizing epitopes representing E1 and
E2 residues are not expressed in secreted E2 proteins (105).
Additionally, recombinant E1 protein (gt1b), not E2, protected
vaccinated chimpanzees from homologous gt1b viral challenge
(106). Finally, developing an E1E2-specific NAb response may
be a perquisite to mount a successful CMI response for viral
clearance (8, 107). For these reasons, a DNA vaccine encoding
secreted E1-E2 and IMX313P remains a prime candidate for the
development an HCV vaccine.
Thus, far, the correlates of protective immunity against HCV
have not been fully defined. Nevertheless, it is generally accepted
that an effective vaccine against HCV should induce a robust
antibody response capable of neutralizing the virus as well as a
potent, broad CMI, to restrict virus propagation and spread (108,
109). We have previously developed novel DNA vaccines capable
of generating robust CD4+ and CD8+ T cell responses against
NS proteins 3, 4A, 4B, and 5B (51, 52) similar to those observed
during resolution of acute HCV infection. We also recently
showed that a multigenotypic DNA cocktail vaccine encoding
gt1b NS5B proteins and gt3a induced higher CMI responses
to gt1b and gt3a NS5B proteins than a DNA vaccine encoding
a global consensus sequence (49), while a multiantigenic DNA
vaccine cocktail encoding gt1b and gt3a NS3, NS4, and NS5B
proteins significantly improved the responses to NS3 and NS5B
compared to those induced by the individual-genotype vaccines
(49). Further experiments should be conducted to assess whether
a DNA cocktail vaccine comprising the envelope constructs
reported in this study in combination with the DNA vaccine
encoding NS proteins can elicit both anti-E1E2 NAb and CMI
responses to the NS proteins. This strategy will ensure that the
induced antibodies will either prevent HCV infection of host
cells or reduce the number of HCV-infected hepatocytes that
will in turn be eliminated by the CD8+ T cell response. In fact,
the induction of a broad CMI may be seminal to protect against
infection with heterologous HCV strains (110, 111).
In summary, these results have significant implications
for the design and development of a HCV prophylactic
vaccine and demonstrate the flexibility and unique ability of
the sE1/sE2-IMX313P strategy to elicit HCV-specific immune
responses after homologous and heterologous prime-boost
immunization. These results also support further development
and testing of these vaccine constructs in larger animals, most
likely in combination with DNA vaccines which elicit CMI.
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